Explore the vast range of titles available.

Introduction As ceRNA network of long non-coding RNA (lncRNA)–microRNA (miR)–messenger RNAs (mRNA) can be predicted on the basis of bioinformatics tools, we are now one step closer to deeper understanding carcinogenic mechanisms. In this study, we clarified the mechanistic understanding of JHDM1D-AS1-miR-940-ARTN ceRNA network in the development of breast cancer (BC). Materials and Methods The lncRNA–miRNA–mRNA interaction of interest was predicted by in silico analysis and identified by conducting RNA immunoprecipitation, RNA pull-down and luciferase assays. The expression patterns of JHDM1D-AS1, miR-940 and ARTN in BC cells were altered by lentivirus infection and plasmid transfection for functional assays on the biological properties of BC cells. Finally, the tumorigenic and metastatic abilities of BC cells were assessed in vivo. Results JHDM1D-AS1 was highly expressed, while miR-940 was poorly expressed in BC tissues and cells. JHDM1D-AS1 could competitively bind to miR-940, whereby promoting the malignant behaviors of BC cells. Furthermore, ARTN was identified as a target gene of miR-940. Through targeting ARTN, miR-940 exerted a tumor-suppressive role. In vivo experiments further confirmed that JHDM1D-AS1 enhanced the tumorigenesis and metastasis through up-regulation of ARTN. Conclusions Taken together, our study demonstrated the involvement of ceRNA network JHDM1D-AS1-miR-940-ARTN in the progression of BC, which highlighted promising therapeutic targets for BC treatment.

R459.3; 目的 了解国内ICU收治患者的营养治疗实施状况.方法 对国内116家医院的118个ICU内的患者进行营养治疗实施状况的横断面调查.以2017年4月26日0时所有在ICU内治疗的患者为调查对象,收集患者基本信息、2017年4月25日(即调查日)的营养实施和胃肠道耐受情况,以及患者的28 d临床转归情况.结果 调查共收集病例1953例,女631例(32.4％),男1306例(66.9％),缺失16例(0.7％);年龄(64.1±19.3)岁(1950例).患者GCS、SOFA和APACHEⅡ评分分别为(10.76±4.35)分(1749例)、(5.65±3.52)分(1783例)、(17.14±7.31)分(1792例).28 d临床转归存活1483例(75.9％),死亡312例(16.0％),失访+缺失158例(8.1％).除身高和体重(P=0.000)外,男性与女性患者在年龄、病情严重程度及28 d临床转归等方面差异均无统计学意义.1953例患者中,胃肠功能评估为正常或轻度损害占73.7％(1440例),中-重度损害占10.8％(210例),衰竭占1.7％(33例),13.2％(258例)的患者未做评估.截至调查日,69.4％(1356例)的患者已启动肠内营养(EN),36.4％(711例)的患者已启动肠外营养(PN).调查日有营养摄入的患者1720例(88.1％).1953例患者中明确有恶心、呕吐反流、误吸、腹痛、腹胀、腹泻(大便次数≥3次/d且量≥500 ml/d)等胃肠道不耐受表现的分别占总人数的4.8％(93例)、5.4％(105例)、0.9％(17例)、8.7％(170例)、27.5％(538例)和4.3％(84例).在1270例使用EN的病例中,明确存在恶心、呕吐反流、误吸、腹痛、腹胀、腹泻等不耐受症状的分别占3.2％(40例)、4.3％(54例)、0.8％(10例)、4.4％(56例)、26.9％(341例)和5.4％(69例).入ICU后24 h内开始EN治疗的患者占22.4％(437/1953),48 h内开始的占38.6％(754/1953),72 h内开始的占46.6％(911/1953).患者入ICU后3 d总热卡(EN+PN非蛋白热卡)达标率为12.9％(78/607),7 d总热卡达标率为18.7％(189/1010),14 d总热卡的达标率为23.0％(305/132